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OBJECTIVE: The purpose of this study is to evaluate 
the effect of an evidence-based asthma disease manage-
ment program in patients’ health-related quality of life
(HRQL). METHODS: A total of 54 asthmatic adult
patients participated in the before and-after study in one
of the managed care organisations in Hungary. The
program included the development and use of evidence-
based protocols, patient education, asthma nurse consul-
tation and self-management programs. On entering the
study, after 6 months and after 12 months patients’
HRQL was measured using the generic utility question-
naire, the EQ-5D and the speciﬁc Asthma Quality of Life
Questionnaire (AQLQ). Statistical signiﬁcance was tested
with paired samples T-test. RESULTS: A total of 24
patients completed the questionnaires on all 3 occasions.
The mean baseline score was 0.79, 69.95, and 4.16 for
the EQ-5D index, EQ-5D VAS, and the AQLQ overall,
respectively. Baseline scores of patients with and without
complete follow-up data did not differ from each other.
At 6 months there was a signiﬁcant mean increase of 
0.11 (p = 0.007) and 10.0 (p = 0.004) in the index and
the VAS scores, respectively. After 12 months, the index
score was maintained at 0.89, with a mean increase of
0.10 from baseline (p = 0.013). The VAS score continued
to grow to 84.48 reﬂecting an overall increase of 14.53
(p < 0.001). At 12 months, signiﬁcantly less patients
reported problems in mobility and anxiety/depression.
Both the domain levels and overall AQLQ scores
improved at 6 months (p < 0.001). At 12 months, this
change remained signiﬁcant. Improvements in Symptom
and Emotion domains were large, 0.84 (p < 0.001) and
0.82 (p < 0.001) respectively. CONCLUSIONS: Evi-
dence-based asthma disease management programs can
signiﬁcantly improve patients’ HRQL already after 6
months, and this improvement can be maintained after
12 months. Importantly, the magnitude of achievable
improvement in HRQL corresponded to a difference pre-
viously observed between two asthma disease control
level groups.
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OBJECTIVES: Aortic valve replacement surgery has
become increasingly common. One of the primary issues
in choice of valve is patient quality of life. We obtained
SF-36 scores on patients following aortic valve replace-
ment surgery to determine how they compared with 
community norms and across valve types. METHODS:
Operative data were obtained from an adult cardiac
surgery database maintained by the department and con-
forming to STS data element deﬁnitions where applica-
ble. All patients receiving aortic valve replacement
between January 1992 and July 1997 were sent quality
of life surveys in the mail. SF-36 scores were calculated
using algorithms provided by QualityMetric Incorporated
and compared to general US population means and
between valve types (mechanical, bioprosthetic, or stent-
less bioprosthetic). RESULTS: Of 743 eligible patients,
329 returned the QOL surveys (43%). There were no dif-
ferences in age, gender or surgery type between patients
who did and did not return their surveys. Means on all
SF-36 subscales were comparable between valve patients
and Age 65–74 population norms. The greatest decre-
ment was seen in the general health item. Population
mean versus valve patient mean were as follows: PF 44.5
vs. 44.1; RP 45.5 vs. 44.1; BP 47.8 vs. 50.8; GH 48.4 vs.
46.0; VT 51.6 vs. 50.1; SF 50.1 vs. 50.2; RE 48.63 vs.
46.5; MH 52.7 vs. 52.1. Valve type had no effect on SF-
36 subscales. CONCLUSIONS: Aortic valve replacement
surgery provides patients with general quality of life
equivalent to that of the US population in the same age
group. All types of valves appear to have equivalent
effects on quality of life. Further study with more spe-
cialized measurement instruments are necessary to deter-
mine whether there are more disease speciﬁc differences
in quality of life following aortic valve replacement
surgery.
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OBJECTIVE: The purpose of this study was to examine
the economic and quality of life (QoL) impact of seasonal
allergic conjunctivitis in Oxfordshire. METHODS: Par-
ticipants were recruited from either general practices, or
the casualty department of the Oxford Eye Hospital
(OEH). The inclusion criteria for cases were that partic-
ipants: 1) experienced itchy, bloodshot and watering eyes
at some time between February and August every year
since 1999, and 2) considered it likely that this was in
response to seasonal allergens. Participants completed the
EQ-5D Health Questionnaire, the Rhinoconjunctivitis
Quality of Life Questionnaire, the National Eye Institute
(US) Visual Functioning Questionnaire 25, and a specially
developed Health Economic and Demographic Question-
naire. RESULTS: Most participants in both groups were
female (67.5% in SAC and 70% in control group, P =
0.565). Weekly earnings were lower in the SAC group 
(P < 0.001), as the SAC group also worked fewer hours
per week (P < 0.001). Participants with SAC also experi-
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enced a greater degree of pain and discomfort as mea-
sured by the EQ-5D (P = 0.018) and a lower perception
of their health status using the EQ-VAS (P = 0.039). 
Statistically signiﬁcant differences between both groups
were detected in all domains of the VFQ-25, except
general and colour vision, although differences were
thought to be clinically signiﬁcant only for the ocular pain
domain. The RQLQ scores were also all found to differ
signiﬁcantly between groups (P < 0.001). The total of
both the public health care and private out-of-pockets
costs of SAC in our study population ranged on average
between £64.61 for a pensioner to £142.29 for a person
with SAC in paid employment. CONCLUSIONS: SAC is
a costly, highly prevalent, chronic condition associated
with signiﬁcant reductions in both ocular and general
quality of life, as well as ongoing out-of-pocket expenses
and health care costs.
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OBJECTIVES: To estimate the number of quality
adjusted life years (QALYs) for chronic, treatment-
resistant heroin addicts in the Netherlands during the 
ﬁrst year of treatment with either oral methadone alone
or oral methadone in combination with co-prescribed
heroin. METHODS: Randomly assigned patients (N =
430) completed EuroQol-5D questionnaires at months 2,
6, 10, and 12 after they started therapy. Utility values
were derived by applying existing time trade-off based
regression weights to the data. It was assumed that the
observed EuroQol scores and related utilities reﬂected 
the health status between the actual measurement and the
previous one available. In case of missing endpoint assess-
ments, the last observation was carried forward. QALYs
were calculated as the mean health utility during follow-
up, weighted for the number of months preceding each
follow-up measurement. It was hypothesized that co-
prescription of heroin would lead to more QALYs.
RESULTS: About half of all treatment-resistant heroin
addicts suffered pain or discomfort and felt anxious or
depressed at baseline. In the ﬁrst year of treatment, a
patient on oral methadone alone generated 0.830 QALYs
on average (upper bound one-sided 95% conﬁdence
interval: 0.846), a patient on co-prescribed heroin 0.867
QALYs (lower bound one-sided 95% conﬁdence interval:
0.852). The numbers of QALYs generated per patient dif-
fered for the two groups (t = -2.72, p = 0.003 one-tailed).
Hence, the medical co-prescription of heroin resulted, on
average, in a 21.4% reduction of existing health loss.
CONCLUSIONS: Medical co-prescription of heroin in
addition to an oral methadone regimen is superior to an
oral methadone alone regimen. Further study will focus
on the cost-utility of co-prescribed heroin in this patient
population with special attention to the balance of
increasing health care costs and decreasing costs of illegal




THERAPY, COGNITIVE BEHAVIOUR THERAPY
AND THEIR COMBINATION FOR PEOPLE WITH
BULIMIA NERVOSA IN THE UK
Simon J1,Whittington C2, the Eating Disorders Guideline
Development Group OBO2
1Health Economics Research Centre, University of Oxford,
Oxford, United Kingdom; 2National Collaborating Centre for
Mental Health, National Institute for Clinical Excellence,
London, United Kingdom
OBJECTIVES: Bulimia nervosa (BN) is characterised by
recurrent episodes of binge eating and secondly by com-
pensatory behaviour to prevent weight gain. Its preva-
lence has been estimated between 0.5% and 1.0% in
young women. A recent clinical guideline was commis-
sioned to establish the optimum clinical management of
BN in the UK. Antidepressants and bulimia nervosa spe-
ciﬁc cognitive behaviour therapy (CBT-BN) were identi-
ﬁed as the leading pharmacological and psychological
therapies in the clinical review. This study reports the
results of the cost-effectiveness analysis of these strategies
conducted as part of the guideline development process.
METHODS: A decision analytic model was developed to
calculate the incremental cost-effectiveness of antidepres-
sant therapy (ﬂuoxetine), CBT-BN and their combination
from the NHS’s viewpoint. Remission data were obtained
from the guideline meta-analyses, resource use data were
collected from the literature and experts. Unit costs were
calculated for year 2002/03. Different baseline scenarios
and uncertainty around the estimates (probabilistic analy-
sis) were explored. RESULTS: Combination therapy is
dominated by the other two strategies and was excluded
from the ﬁnal calculation. CBT-BN is more effective and
has higher treatment costs than ﬂuoxetine prescribed in
primary care with an incremental cost-effectiveness ratio
(ICER) of £4,807. The probability of CBT-BN being cost-
effective is 50% if decision makers are willing to pay
between £4,000–£5,000 for an additional successfully
treated BN case, but it increases to approximately 95%
if the threshold value is £10,000. CONCLUSIONS: Sig-
niﬁcant uncertainty around these results still exists (e.g.
the true cost of side effects of antidepressant therapy are
unknown, nor have attempts been made to quantify pos-
sible costs averted due to successful treatment). When
further research is carried out, it will be necessary to re-
estimate the cost-effectiveness of each alternative incor-
porating such inﬂuences. However, all these inﬂuences are
